All relevant data are contained in the paper.

Background {#sec005}
==========

Worldwide up to 185 million people have been infected with the hepatitis C virus (HCV) and as a result of the infection and long-term consequences 350,000 people die every year \[[@pone.0169401.ref001]\]. Estimates assume that about 27% of liver cirrhosis and 25% of hepatocellular carcinoma are attributable to chronic HCV \[[@pone.0169401.ref002]\]. Data from the German National Health and Examination Survey (DEGS1) show an anti HCV-prevalence of 0.3% in Germany \[[@pone.0169401.ref003]\]. Considering a higher prevalence in risk-groups such as drug abuser and prison inmates, recent studies estimate number of infected people at 275,000 \[[@pone.0169401.ref004]\]. The majority of the patients are infected with HCV genotype 1 or 3 \[[@pone.0169401.ref005]\]. A large part of infected patients are unaware of their disease and most infections remain undiagnosed until serious, and potentially lethal, complications such as liver cirrhosis and hepatocellular carcinoma occur \[[@pone.0169401.ref006]\].

The historical dual therapy with pegylated interferon and ribavirin (PegIFN/RBV) was the standard of care for a decade until first generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were approved for the treatment of patients with HCV genotype 1 in 2011. Treatment options significantly improved with the introduction of first interferon-free treatment regimens starting in SOF in January 2014. Other direct acting antivirals (DAAs) simeprevir (SMV), daclatasvir (DCV), sofosbuvir/ledipasvir (SOF/LDV) and combination treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMV/PTV/RTV+DSV) subsequently followed. New treatments have sustained virologic response (SVR) rates of \>90%, a favorable toxicity profile, a shorter treatment duration and thus enable to cure most patients. New DAAs are recommended for treatment by current AASLD, EASL and German guidelines whereby the latter primarily focus on interferon-free treatments which have been evaluated in phase-3 trials. In genotype 1 patients only treatment with SOF/LDV±RBV and OMV/PTV/RTV+DSV±RBV are recommended without any restrictions. Therapeutic advances were accompanied by an increase in treatment costs raising the question if high costs are justified and affordable for healthcare systems, even in western countries. After introduction, several European countries have limited the access to new DAAs and primarily treat patients with advanced HCV-infection in order to control HCV-related health expenditure.

Up to now, several analyses have estimated cost-effectiveness of newly introduced treatment regimens \[[@pone.0169401.ref007]--[@pone.0169401.ref010]\]. Nevertheless, studies including recently introduced interferon-free regimens SOF/LDV±RBV and OMV/PTV/RTV+DSV±RBV are rare and usually refer to the US healthcare system. Furthermore, latest guideline recommendation on treatment regimen considering treatment duration and the use of RBV are usually not considered.

For example, Younossi et al. (2015) analyzed cost-effectiveness of SOF/LDV regimens in patients with genotype 1 infection \[[@pone.0169401.ref007]\]. They showed that LDV/SOF treatment dominates all previous treatments in treatment-naive and treatment-experienced patients, except for treatment with SOF/SMV which shows marginally better outcomes but considerably higher costs. Treatment with OMV/PTV/RTV+DSV was not considered \[[@pone.0169401.ref007]\]. Two other US studies evaluating SOF/LDV treatment determined higher lifetime costs and better outcomes compared to old standard of care. Both studies conclude that SOF/LDV could be considered as cost-effective \[[@pone.0169401.ref008];[@pone.0169401.ref009]\].

The aim of the present study was to assess the long-term cost-effectiveness of treating chronic hepatitis C genotype 1 patients with SOF/LDV in Germany based on current German guidelines.

Methods {#sec006}
=======

Study Design {#sec007}
------------

We used a Markov cohort model to determine the cost-effectiveness (long-term outcomes and costs) of treating chronic hepatitis C genotype 1 patients with sofosbuvir/ledipasvir ± Ribavirin (LDV/SOF±RBV). The study was conducted from the perspective of the German healthcare system. An annual discount-rate of 3% was used as recommended by the German Institute for Quality and Efficiency in Health Care (IQWiG) \[[@pone.0169401.ref011]\]. The model was programmed with Microsoft Excel.

Outcomes {#sec008}
--------

To analyze long-term cost-effectiveness we calculated lifetime costs and quality-adjusted life years (QALYs) and derived incremental cost-effectiveness ratios (ICER) for different treatment strategies.

Study Population {#sec009}
----------------

Our base-case was a hypothetical cohort of 10,000 patients. Treatment-naive patients initiate treatment at an age of 40 years and treatment-experienced patients at an age of 45 years. Patients were stratified according to the presence/absence of liver cirrhosis. We assumed an average weight of 80kg for weight-based medications.

Treatment Strategies and Effectiveness {#sec010}
--------------------------------------

Treatment strategies of LDV/SOF±RBV as well as alternative regimens depend on treatment status (treatment-naive vs. treatment-experienced) and presence/absence of cirrhosis. Treatment-naive non-cirrhotic patients received 8 or 12 weeks of LDV/SOF depending on baseline viral load; cirrhotic patients received 12 weeks of LDV/SOF+RBV. We assumed, based on data from the German Hepatitis C Registry, that 90.7% of treatment-naive patients had viral load \<6 Mio IU/ml and qualify for 8 weeks of treatment. Treatment experienced non-cirrhotic patients received 12 weeks of LDV/SOF and cirrhotic patients additionally received RBV. Alternative treatment strategies and effectiveness data are summarized in [Table 1](#pone.0169401.t001){ref-type="table"}. Treatments are based on current German guidelines and EASL guidelines. Effectiveness data for each patient group was derived from clinical trials and summary of product characteristics. We assumed a GT-1a/b ratio of 47%/53% based on recent data \[[@pone.0169401.ref012]\].

10.1371/journal.pone.0169401.t001

###### Treatment regimens.
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  Treatment regimen   Treatment duration          SVR-rate (Range)           Source:                   
  ------------------- --------------------------- -------------------------- ------------------------- --------------------------------------------------------------------------
                      **Treatment naive**                                                              
                      **non-cirrhotic:**                                                               
                      SOF/LDV                     8 or 12 weeks              96.8% (91.8% - 100.0%)    \[[@pone.0169401.ref013]--[@pone.0169401.ref015]\]
                      SOF + PegIFN + RBV          12 weeks                   92.3% (88.5% - 95.2%)     \[[@pone.0169401.ref016];[@pone.0169401.ref017]\]
                      PTV/r/OMV/DSV ± RBV         12 weeks                   98.1% (93.1% - 99.9%)     \[[@pone.0169401.ref018]--[@pone.0169401.ref020]\]
                      SOF+RBV                     24 weeks                   67.6% (60.0% - 75.0%)     \[[@pone.0169401.ref017]\]
                      SMV + PegIFN + RBV          24 weeks                   82.0% (78.0% - 85.0%)     \[[@pone.0169401.ref021]--[@pone.0169401.ref023]\]
                      SOF + DCV                   12 weeks                   100.0% (95.0% - 100.0%)   \[[@pone.0169401.ref024];[@pone.0169401.ref025]\]
                      SOF + SMV                   12 weeks                   94.1% (79.4% - 99.8%)     \[[@pone.0169401.ref026]\]
                      TVR + PegIFN + RBV          24 or 48 weeks             77.3% (74.8% - 79.7%)     \[[@pone.0169401.ref027]\]
                      BOC + PegIFN + RBV          28 or 48 weeks             64.1% (60.2% - 67.9%)     \[[@pone.0169401.ref028]\]
                      PegIFN + RBV                48 weeks                   43.6% (40.3% - 46.9%)     \[[@pone.0169401.ref029]\]
                      **cirrhotic:**                                                                   
                      SOF/LDV +RBV                12 weeks                   98.0% (94.5% - 99.8%)     \[[@pone.0169401.ref015];[@pone.0169401.ref030]\]
                      SOF + PegIFN + RBV          12 weeks                   79.6% (66.5% - 89.4%)     \[[@pone.0169401.ref016];[@pone.0169401.ref017]\]
                      PTV/r/OMV/DSV + RBV         12 (1b) or 24 weeks (1a)   97.5% (88.9% - 99.1%)     \[[@pone.0169401.ref018]--[@pone.0169401.ref020]\]
                      SOF+RBV                     24 weeks                   36.4% (12.2% - 65.2%)     \[[@pone.0169401.ref017]\]
                      SMV + PegIFN + RBV          24 weeks                   60.4% (46.4% - 73.6%)     \[[@pone.0169401.ref021]--[@pone.0169401.ref023]\]
                      SOF + DCV                   12 weeks                   100.0% (95.0% - 100.0%)   \[[@pone.0169401.ref024];[@pone.0169401.ref025]\]
                      SOF+SMV                     12 weeks                   92.9% (66.5% - 99.9%)     \[[@pone.0169401.ref026]\]
                      TVR + PegIFN + RBV          24 or 48 weeks             53.4% (44.9% - 61.9%)     \[[@pone.0169401.ref027]\]
                      BOC + PegIFN + RBV          48 weeks                   55.0% (42.4% - 67.3%)     \[[@pone.0169401.ref028]\]
                      PegIFN + RBV                48 weeks                   23.6% (16.2% - 32.0%)     \[[@pone.0169401.ref029]\]
                      **Treatment experienced**                                                        
                      **non-cirrhotic:**                                                               
                      SOF/LDV                     12 weeks                   95.4% (90.1% - 98.7%)     \[[@pone.0169401.ref015];[@pone.0169401.ref031]\]
                      SOF + PegIFN + RBV          12 weeks                   78.0% (68.0% - 88.0%)     \[[@pone.0169401.ref032]\]
                      PTV/r/OMV/DSV ± RBV         12 weeks                   98.1% (91.3% - 99.0%)     \[[@pone.0169401.ref033];[@pone.0169401.ref034]\]
                      SMV + PegIFN + RBV          48 weeks                   76.5% (71.6--81.0%)       \[[@pone.0169401.ref023];[@pone.0169401.ref035];[@pone.0169401.ref036]\]
                      SOF + DCV                   12 weeks                   95.4% (90.1% - 98.7%)     Assumption: equal to SOF/LDV
                      SOF + SMV                   12 weeks                   92.9% (66.5% - 99.9%)     \[[@pone.0169401.ref023];[@pone.0169401.ref026]\]
                      TVR + PegIFN + RBV          24 or 48 weeks             72.2% (65.7% - 78.2%)     \[[@pone.0169401.ref037];[@pone.0169401.ref038]\]
                      BOC + PegIFN + RBV          48 weeks                   64.4% 56.1% - 72.3%)      \[[@pone.0169401.ref039];[@pone.0169401.ref040]\]
                      PegIFN + RBV                48 weeks                   17.6% (10.9% - 25.6%)     \[[@pone.0169401.ref037];[@pone.0169401.ref038]\]
                      **cirrhotic:**                                                                   
                      SOF/LDV +RBV                12 weeks                   96.1% (90.8% - 99.2%)     \[[@pone.0169401.ref015];[@pone.0169401.ref030]\]
                      SOF + PegIFN + RBV          12 weeks                   71.0% (61.0% - 81.0%)     \[[@pone.0169401.ref032]\]
                      PTV/r/OMV/DSV + RBV         12 (1b) or 24 weeks (1a)   96.7% (90.8% - 98.9%)     \[[@pone.0169401.ref020];[@pone.0169401.ref041]\]
                      SMV + PegIFN + RBV          48 weeks                   66.7% (54.7% - 77.7%)     \[[@pone.0169401.ref023];[@pone.0169401.ref035];[@pone.0169401.ref036]\]
                      SOF + DCV                   12 weeks                   86.4% (69.6% - 97.0%)     Assumption: equal to SOF/LDV
                      SOF+SMV                     12 weeks                   92.9% (66.5% - 99.9%)     \[[@pone.0169401.ref023];[@pone.0169401.ref026]\]
                      TVR + PegIFN + RBV          48 weeks                   47.2% (35.9% - 58.7%)     \[[@pone.0169401.ref037];[@pone.0169401.ref038]\]
                      BOC + PegIFN + RBV          48 weeks                   35.3% (15.2% - 58.7%)     \[[@pone.0169401.ref039];[@pone.0169401.ref040]\]
                      PegIFN + RBV                48 weeks                   10.0% (2.2% - 22.8%)      \[[@pone.0169401.ref037];[@pone.0169401.ref038]\]

Model Structure {#sec011}
---------------

The model reflects the natural course of the infection and simulates the lifetime progression of patients with chronic HCV infection. After initiating treatment patients were followed over a lifetime (lifetime horizon). Progression is characterized by different stages of disease severity based on the METAVIR score ([Fig 1](#pone.0169401.g001){ref-type="fig"}).

![Model schematic.](pone.0169401.g001){#pone.0169401.g001}

In non-cirrhotic patients disease progression is stopped after achieving SVR. Patients with cirrhosis could develop decompensated cirrhosis or hepatocellular carcinoma even after achieving SVR whereas probability of progression is significantly reduced compared to patients without SVR. To facilitate the modeling of different treatment strategies and the transition to SVR, cycle-length is monthly for the first one and a half years and next two cycles are quarterly. From year two after initiation of treatment, transition occurs on a yearly basis. We assumed a split for mild and moderate patients based on the proportion of patients with a METAVIR score of F0-F2 (mild) and F3 (moderate) in ION trials, which is 78% and 22%.Transition probabilities were derived from published literature [Table 2](#pone.0169401.t002){ref-type="table"} \[[@pone.0169401.ref042]--[@pone.0169401.ref046]\]. All-cause mortality rates were derived from the German Federal Statistical Office \[[@pone.0169401.ref047]\].

10.1371/journal.pone.0169401.t002

###### Model inputs.
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  Transition probabilities                                                              Base-Case                           Range/Variation      Source
  ---------------------------------------------- -------------------------------------- ----------------------------------- -------------------- ---------------------------------------------------
  **Health State**                                                                                                                               
  **From:**                                      **To:**                                **Annual transition probability**                        
  Non-cirrhotic                                  Compensated cirrhosis (age 30 years)   0.006                               0.003--0.010         \[[@pone.0169401.ref042]\]
                                                 Compensated cirrhosis (age 40 years)   0.009                               0.005--0.015         \[[@pone.0169401.ref042]\]
                                                 Compensated cirrhosis (age 50 years)   0.016                               0.008--0.026         \[[@pone.0169401.ref042]\]
  Compensated cirrhosis                          Decompensated cirrhosis                0.044                               0.029--0.058         \[[@pone.0169401.ref043]\]
                                                 Hepatocellular carcinoma               0.063                               0.046--0.080         \[[@pone.0169401.ref043]\]
  Compensated cirrhosis (SVR)                    Decompensated cirrhosis                0.006                               0.000--0.013         \[[@pone.0169401.ref043]\]
                                                 Hepatocellular carcinoma               0.013                               0.003--0.022         \[[@pone.0169401.ref043]\]
  Decompensated cirrhosis                        Hepatocellular carcinoma               0.014                               0.002--0.039         \[[@pone.0169401.ref044]\]
                                                 Liver Transplant                       0.022                               0.011--0.033         \[[@pone.0169401.ref045]\]
                                                 Death                                  0.130                               0.111--0.150         \[[@pone.0169401.ref044]\]
  Hepatocellular carcinoma                       Death                                  0.430                               0.372--0.489         \[[@pone.0169401.ref044]\]
  Liver transplant                               Death                                  0.210                               0.127--0.307         \[[@pone.0169401.ref046]\]
  Post Liver Transplant                          Death                                  0.057                               0.037--0.082         \[[@pone.0169401.ref046]\]
  **Quality of life utilities**                                                                                                                  
  **Health State**                                                                      **Utility**                                              
  Non Cirrhotic                                                                         0.81                                0.73--0.90           \[[@pone.0169401.ref048]\]
  Compensated Cirrhosis                                                                 0.74                                0.67--0.78           \[[@pone.0169401.ref048]\]
  Decompensated Cirrhosis                                                               0.72                                0.66--0.79           \[[@pone.0169401.ref048]\]
  Hepatocellular Carcinoma                                                              0.72                                0.66--0.79           \[[@pone.0169401.ref048]\]
  Liver Transplant                                                                      0.72                                0.66--0.79           \[[@pone.0169401.ref048]\]
  Post Liver Transplant                                                                 0.79                                0.66--0.92           \[[@pone.0169401.ref048]\]
  QoL increase if SVR is achieved                                                       0.041                               0.024--0.063         \[[@pone.0169401.ref049]\]
  QoL Increment SOF/LDV                                                                 \+ 4.43%                            +3.30% to +5.73%     Data on file
  QoL Increment SOF/LDV + RBV                                                           \- 3.25%                            -1.55% to -5.56%     Data on file
  QoL Increment SOF + PegIFN + RBV                                                      \- 14.52%                           -11.15% to -18.33%   Data on file
  QoL Increment TVR + PegIFN + RBV                                                      \- 14.27% (TN) / - 14.61% (TE)      -12.37% to -16.29%   \[[@pone.0169401.ref050]\]
  QoL Increment BOC + PegIFN + RBV                                                      \- 12.20%                           -10.28% to 14.28%    \[[@pone.0169401.ref051]\]
  QoL Increment PegIFN + RBV                                                            \- 14.75%                           -6.31% to -26.71%    \[[@pone.0169401.ref046]\]
  SOF + DAC                                                                             \+ 4.43%                            +3.30% to +5.73%     Assumption: equal to SOF/LDV
  SOD + SMV                                                                             \+ 4.43%                            +3.30% to +5.73%     Assumption: equal to SOF/LDV
  QoL Increment SMV + PegIFN + RBV                                                      \- 14.27% (TN) / - 14.61% (TE)      -12.37% to -16.29%   Assumption: equal to TVR + PegIFN + RBV
  QoL Increment PTV/r/OMV/DSV                                                           \+ 4.43%                            +3.30% to +5.73%     Assumption: equal to SOF/LDV
  QoL Increment PTV/r/OMV/DSV + RBV                                                     \- 3.25%                            -1.55% to -5.56%     Assumption: equal to SOF/LDV + RBV
  **Pharmaceuticals, € per week**                                                                                                                \[[@pone.0169401.ref052]\]
  SOF/LDV                                                                               4,721                               no variation         
  SOF                                                                                   3,963                               no variation         
  DAC                                                                                   2,241                               no variation         
  SMV                                                                                   2,339                               no variation         
  BOC                                                                                   786                                 no variation         
  TVR                                                                                   2,339                               no variation         
  PegIFN-α2a                                                                            254                                 no variation         
  PegIFN-α2b                                                                            274                                 no variation         
  RBV                                                                                   177                                 no variation         
  OMV/r/PTV                                                                             3,807                               no variation         
  DSV                                                                                   372                                 no variation         
  **Health state costs, € per year**                                                                                                             \[[@pone.0169401.ref053];[@pone.0169401.ref054]\]
  Mild HCV                                                                              153                                 ± 25%                
  Moderate HCV                                                                          157                                 ± 25%                
  Compensated cirrhosis                                                                 776                                 ± 25%                
  Decompensated cirrhosis                                                               9,768                               ± 25%                
  HCC                                                                                   24,096                              ± 25%                
  Liver transplantation incl. 1^st^ year                                                143,480                             ± 25%                
  Liver transplantation follow-up \>1^st^ year                                          20,751                              ± 25%                
  **On treatment costs**                                                                                                                         Updated from \[[@pone.0169401.ref055]\]
  Baseline diagnostics non-cirrhotic                                                    298                                 no variation         
  Baseline diagnostics cirrhotic                                                        305                                 no variation         
  Monitoring 8 weeks non PR                                                             284                                 no variation         
  Monitoring 12 weeks non PR                                                            412                                 no variation         
  Monitoring 24 weeks non PR                                                            568                                 no variation         
  Monitoring 12 weeks with PegIFN and/or RBV                                            431                                 no variation         
  Monitoring 24 weeks with PegIFN and/or RBV                                            592                                 no variation         
  Monitoring 48 weeks with PegIFN and/or RBV                                            800                                 no variation         
  **Adverse event management costs, €**                                                                                                          
  Nausea                                                                                31                                  no variation         
  Vomiting                                                                              31                                  no variation         
  Diarrhoea                                                                             48                                  no variation         
  Pruritus                                                                              15                                  no variation         
  Rash                                                                                  33                                  no variation         
  Anaemia (blood transfusion)                                                           19                                  no variation         
  Depression                                                                            7                                   no variation         

Quality of Life Data {#sec012}
--------------------

Health state utilities reflect the quality of life of HCV-infected patients in each health state on a scale from 1 (perfect health) to 0 (death). Information was derived from a study by Siebert et al (2003) who used EuroQoL-5D for determination of quality of life in HCV patients \[[@pone.0169401.ref048]\]. Information on reduction in quality of life during antiviral treatment was derived from clinical study reports or published literature. If no information were available for certain therapies, data from other treatments were used as an approximation ([Table 2](#pone.0169401.t002){ref-type="table"}).

Cost Data {#sec013}
---------

Costs of treating hepatitis C included treatment associated costs and costs of disease progression (health state costs). Treatment costs comprise pharmaceuticals, costs for diagnostic procedures related to basic diagnostics for treatment initiation and on-treatment monitoring as well as adverse event management. Information on pharmaceutical costs were derived from the German drug directory (Lauer-Taxe) \[[@pone.0169401.ref052]\]. Costs for diagnostic procedures were adapted and updated from a published study on guideline-based treatment costs \[[@pone.0169401.ref055]\]. Costs for adverse event management covers prescribed medication on expert opinion. Health state costs were derived from published literature and inflated to 2015 \[[@pone.0169401.ref053];[@pone.0169401.ref054];[@pone.0169401.ref056]\]. Cost data are summarized in [Table 2](#pone.0169401.t002){ref-type="table"}.

Sensitivity Analyses {#sec014}
--------------------

We performed deterministic (DSA) and probabilistic sensitivity analyses (PSA) to evaluate the robustness of the model and to examine the effect of uncertainty on primary outcomes. For variation of SVR-rates, quality of life and transition probabilities 95%-confidence intervals were used or calculated based on distribution assumptions. Health state costs were varied by ±25% as no detailed information on point estimates is available. Single components of treatment costs (basic diagnostic procedures, monitoring, pharmaceuticals and adverse event management costs) were not varied separately but varied as a whole by ±25%. The PSA is based on Monte Carlo simulation with 1,000 iterations. In this analysis all variables are varied simultaneously according to their distributions. We assumed beta distribution for SVR-rates, transition probabilities and quality of life utilities estimates. Gamma distribution was used for treatment costs, health state costs and utility decrements.

Results {#sec015}
=======

Base-Case Results {#sec016}
-----------------

The results of our base-case analysis were stratified for treatment-naive and treatment-experienced patients as well as absence/presence of liver cirrhosis and show average lifetime costs and outcomes for different treatment strategies ([Table 3](#pone.0169401.t003){ref-type="table"}). Incremental cost effectiveness ratios were calculated comparing different regimens to recent standard of care with TVR +PR. Additionally, we compared SOF/LDV±RBV to other treatment regimens.

10.1371/journal.pone.0169401.t003

###### Base-Case Analysis Results.
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  Treatment regimen           lifetime costs, €   QALYs    ICER (vs. TVR+PR), € per QALY                     ICER (vs. SOF/LDV), € per QALY
  --------------------------- ------------------- -------- ------------------------------------------------- -------------------------------------------------
  **Treatment naive**                                                                                        ** **
  **combined cohorts**                                                                                       ** **
  SOF/LDV ± RBV               53.828              18,659   850                                               **reference**
  SOF + PegIFN + RBV          62.912              18,271   13.692                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  PTV/r/OMV/DSV ± RBV         66.869              18,680   12.258                                            621.204
  SOF+RBV                     114.151             17,092   [\~](#t003fn001){ref-type="table-fn"} dominated   [\~](#t003fn001){ref-type="table-fn"} dominated
  SMV + PegIFN + RBV          50.903              17,734   [\#](#t003fn002){ref-type="table-fn"} dominant    3.162
  SOF + DCV                   83.608              18,750   25.351                                            324.749
  SOF + SMV                   85.664              18,530   33.047                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          52.875              17,538   **reference**                                     850
  BOC + PegIFN + RBV          51.787              17,362   6.182                                             1.574
  PegIFN + RBV                34.385              16,486   17.583                                            8.951
  no treatment                22.138              15,358   14.101                                            9.602
  **non-cirrhotic:**                                                                                          
  SOF/LDV                     41.056              20,031   [\#](#t003fn002){ref-type="table-fn"} dominant    **reference**
  SOF + PegIFN + RBV          53.999              19,891   29.151                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  PTV/r/OMV/DSV ± RBV         52.490              20,061   17.280                                            381.843
  SOF + RBV                   103.696             19,307   [\~](#t003fn001){ref-type="table-fn"} dominated   [\~](#t003fn001){ref-type="table-fn"} dominated
  SMV + PegIFN + RBV          41.322              19,629   [\#](#t003fn002){ref-type="table-fn"} dominant    -661
  SOF + DCV                   75.557              20,104   55.290                                            475.904
  SOF + SMV                   77.398              19,971   75.541                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          43.073              19,516   **reference**                                     [\~](#t003fn001){ref-type="table-fn"} dominated
  BOC + PegIFN + RBV          40.853              19,220   7.482                                             250
  PegIFN + RBV                23.981              18,748   24.867                                            13.311
  no treatment                11.559              17,831   18.704                                            13.408
  **cirrhotic:**                                           ** **                                              
  SOF/LDV +RBV                93.185              14,429   3.383                                             **reference**
  SOF + PegIFN + RBV          90.376              13,279   3.972                                             2.443
  PTV/r/OMV/DSV + RBV         111.178             14,422   9.428                                             [\~](#t003fn001){ref-type="table-fn"} dominated
  SOF + RBV                   146.371             10,268   [\~](#t003fn001){ref-type="table-fn"} dominated   [\~](#t003fn001){ref-type="table-fn"} dominated
  SMV + PegIFN + RBV          80.425              11,894   [\#](#t003fn002){ref-type="table-fn"} dominant    5.034
  SOF + DCV                   108.418             14,580   8.075                                             100.955
  SOF+SMV                     111.136             14,092   10.589                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          83.080              11,442   **reference**                                     3.383
  BOC + PegIFN + RBV          85.478              11,638   12.256                                            2.761
  PegIFN + RBV                66.446              9,516    8.635                                             5.442
  no treatment                54.737              7,738    7.651                                             5.746
  **Treatment experienced**   ** **               ** **    ** **                                              
  **combined cohorts**                                                                                        
  SOF/LDV ± RBV               66.141              17,442   10.591                                            **reference**
  SOF + PegIFN + RBV          62.836              16,764   19.149                                            4.879
  PTV/r/OMV/DSV ± RBV         66.137              17,486   10.186                                            [\#](#t003fn002){ref-type="table-fn"} dominant
  SMV + PegIFN + RBV          53.655              16,654   [\#](#t003fn002){ref-type="table-fn"} dominant    15.849
  SOF + DCV                   83.933              17,296   30.255                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  SOF + SMV                   84.961              17,358   29.447                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          54.180              16,312   **reference**                                     10.591
  BOC + PegIFN + RBV          54.757              16,037   [\~](#t003fn001){ref-type="table-fn"} dominated   8.102
  PegIFN + RBV                30.325              14,961   17.658                                            14.440
  no treatment                21.024              14,548   18.793                                            15.592
  **non-cirrhotic:**                                       ** **                                              
  SOF/LDV                     57.937              18,676   26.426                                            **reference**
  SOF + PegIFN + RBV          53.956              18,296   62.251                                            10.471
  PTV/r/OMV/DSV ± RBV         52.172              18,714   14.911                                            [\#](#t003fn002){ref-type="table-fn"} dominant
  SMV + PegIFN + RBV          44.433              18,192   15.552                                            27.893
  SOF + DCV                   75.723              18,676   58.796                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  SOF + SMV                   77.165              18,626   67.563                                            [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          43.417              18,127   **reference**                                     26.426
  BOC + PegIFN + RBV          43.754              17,991   [\~](#t003fn001){ref-type="table-fn"} dominated   20.687
  PegIFN + RBV                19.314              17,098   23.436                                            24.478
  no treatment                10.515              16,795   24.701                                            25.205
  **cirrhotic:**                                                                                              
  SOF/LDV +RBV                91.423              13,637   1.397                                             **reference**
  SOF + PegIFN + RBV          90.201              12,044   2.155                                             767
  PTV/r/OMV/DSV + RBV         109.174             13,703   7.319                                             270.711
  SMV + PegIFN + RBV          82.075              11,914   [\#](#t003fn002){ref-type="table-fn"} dominant    5.424
  SOF + DCV                   109.231             13,041   9.430                                             [\~](#t003fn001){ref-type="table-fn"} dominated
  SOF+SMV                     108.985             13,448   7.934                                             [\~](#t003fn001){ref-type="table-fn"} dominated
  TVR + PegIFN + RBV          87.349              10,721   **reference**                                     1.397
  BOC + PegIFN + RBV          88.664              10,015   [\~](#t003fn001){ref-type="table-fn"} dominated   762
  PegIFN + RBV                64.254              8,376    9.849                                             5.164
  no treatment                53.410              7,624    10.961                                            6.322

\~ dominated: treatment is more expensive and less effective

\# dominant: treatment is less expensive and more effective

In treatment-naive patients SOF/LDV±RBV (18.659 QALYs), PTV/r/OMV+DSV±RBV (18.680 QALYs) and SOF+DCV (18.750 QALYs) had highest long-term outcomes. Total lifetime costs were €53,828 (SOF/LDV±RBV), €66,869 (PTV/r/OMV+DSV±RBV) and €83,608 (SOF+DCV). Treating non-cirrhotic patients resulted in higher outcomes and lower total costs compared to cirrhotic patients. ICER compared to previous standard of care (TVR+PegIFN+RBV) was 850 €/QALY for SOF/LDV±RBV, 12,258 €/QALY for PTV/r/OMV+DSV±RBV and 25,351 €/QALY for SOF+DCV. Only treatment with SMV+PegIFN+RBV dominated TVR+PegIFN+RBV (showed higher outcomes and lower costs).

In treatment-experienced patients, regimens containing SOF/LDV±RBV (17.442 QALYs), PTV/r/OMV+DSV±RBV (17.486 QALYs) and SOF+SMV (17.358 QALYs) showed highest outcomes. Average lifetime costs of €66,141 (SOF/LDV±RBV), €66,137 (PTV/r/OMV+DSV±RBV) and €84,961 (SOF+SMV) were calculated. Just as in treatment-naive patients, outcomes were higher and lifetime costs lower in non-cirrhotic treatment-experienced patients. We calculated ICERs of 11.961 €/QALY for SOF/LDV±RBV, 11,957 €/QALY for PTV/r/OMV+DSV±RBV and 30,781 €/QALY for SOF+SMV compared to previous standard of care (TVR+PegIFN+RBV). Stratified data for non-cirrhotic and cirrhotic patients are shown in [Table 3](#pone.0169401.t003){ref-type="table"}.

Compared to prior standard of care, higher SVR-rates in SOF/LDV±RBV and other DAA regimens can help to avoid the development of liver cirrhosis and end-stage liver disease in many patients ([Table 4](#pone.0169401.t004){ref-type="table"}). In non-cirrhotic treatment-naive patients treatment with SOF/LDV can prevent the development of 58 cases of liver cirrhosis, 19 cases of decompensated liver cirrhosis, 28 cases of HCC and 2 liver transplants per 1,000 patients treated compared to prior standard of care (TVR+PegIFN+RBV). Data for cirrhotic patients show that SOF/LDV+RBV (vs. SoC) can prevent 97 cases of decompensated liver cirrhosis, 104 cases of HCC and 13 liver transplants per 1,000 patients treated.

10.1371/journal.pone.0169401.t004

###### Prevented cases of liver cirrhosis, decompensated cirrhosis, HCC and liver transplant compared to SoC (per 1,000 patients treated).

![](pone.0169401.t004){#pone.0169401.t004g}

  Patient group                        Cirrhosis   Decompensated Cirrhosis   HCC       Liver transplant
  ------------------------------------ ----------- ------------------------- --------- ------------------
  **Treatment naive patients**                                                         
  **non-cirrhotic:**                                                                   
  SOF/LDV                              -58         -19                       -28       -2
  SOF + PegIFN + RBV                   -44         -14                       -22       -2
  PTV/r/OMV/DSV ± RBV                  -62         -20                       -30       -2
  SOF + RBV                            29          10                        14        1
  SMV + PegIFN + RBV                   -14         -4                        -7        0
  SOF + DCV                            -68         -22                       -33       -2
  SOF + SMV                            -50         -16                       -25       -2
  TVR + PegIFN + RBV                   **ref**     **ref**                   **ref**   **ref**
  BOC + PegIFN + RBV                   39          13                        19        1
  PegIFN + RBV                         99          32                        49        4
  no treatment                         232         76                        114       8
  **cirrhotic:**                                                                        
  SOF/LDV + RBV                        n.a.        -97                       -104      -13
  SOF + PegIFN + RBV                   n.a.        -57                       -61       -8
  PTV/r/OMV/DSV ± RBV                  n.a.        -96                       -104      -13
  SOF + RBV                            n.a.        38                        41        5
  SMV + PegIFN + RBV                   n.a.        -15                       -16       -2
  SOF + DCV                            n.a.        -102                      -109      -14
  SOF + SMV                            n.a.        -86                       -92       -11
  TVR + PegIFN + RBV                   n.a.        **ref**                   **ref**   **ref**
  BOC + PegIFN + RBV                   n.a.        -4                        -5        -1
  PegIFN + RBV                         n.a.        65                        70        9
  no treatment                         n.a.        118                       128       16
  **Treatment experienced patients**                                                   
  **non-cirrhotic:**                                                                   
  SOF/LDV                              -62         -19                       -29       -2
  SOF + PegIFN + RBV                   -15         -5                        -7        0
  PTV/r/OMV/DSV ± RBV                  -69         -22                       -33       -2
  SMV + PegIFN + RBV                   -12         -4                        -6        0
  SOF + DCV                            -62         -19                       -29       -2
  SOF + SMV                            -55         -17                       -26       -2
  TVR + PegIFN + RBV                   **ref**     **ref**                   **ref**   **ref**
  BOC + PegIFN + RBV                   20          6                         10        1
  PegIFN + RBV                         146         46                        69        5
  no treatment                         195         62                        93        7
  **cirrhotic:**                                                                        
  SOF/LDV + RBV                        n.a.        -110                      -123      -14
  SOF + PegIFN + RBV                   n.a.        -53                       -58       -7
  PTV/r/OMV/DSV + RBV                  n.a.        -111                      -125      -15
  SMV + PegIFN + RBV                   n.a.        -45                       -51       -6
  SOF + DCV                            n.a.        -88                       -98       -11
  SOF + SMV                            n.a.        -102                      -114      -13
  TVR + PegIFN + RBV                   n.a.        **ref**                   **ref**   **ref**
  BOC + PegIFN + RBV                   n.a.        27                        31        4
  PegIFN + RBV                         n.a.        85                        97        11
  no treatment                         n.a.        109                       125       14

n.a.--not applicable; ref--reference treatment

In non-cirrhotic treatment-experienced patients treatment with SOF/LDV can prevent the development of 62 cases of liver cirrhosis, 19 cases of decompensated liver cirrhosis, 29 cases of HCC and 2 liver transplants per 1,000 patients treated compared to TVR+PegIFN+RBV. Data for cirrhotic patients show that SOF/LDV+RBV can prevent 110 cases of decompensated liver cirrhosis, 123 cases of HCC and 14 liver transplants per 1,000 patients treated.

Sensitivity Analysis {#sec017}
--------------------

In one-way sensitivity analysis, we identified the ten variables which have the largest impact on costs per QALY results (SOF/LDV±RBV vs. TVR+PegIFN+RBV). Analyses were performed separately for different subgroups. In treatment-naive non-cirrhotic patients only variation on treatment costs for SOF/LDV and treatment comparator had significant impact leading to the fact of SOF/LDV did not dominate the comparator anymore. In treatment-naive cirrhotic patients, treatment costs of SOF/LDV+RBV and TVR+PegIFN+RBV as well as the discount rate had highest impact on study results. In treatment-experienced patients, highest impacts on results were observed for treatment costs and discount rate as well ([Fig 2](#pone.0169401.g002){ref-type="fig"}).

![Deterministic Sensitivity Analysis Results.](pone.0169401.g002){#pone.0169401.g002}

Robustness of base-case results was confirmed in PSA. Results for treatment-naive non- cirrhotic patients showed that the chance of SOF/LDV for being more effective and less costly is 100%. In treatment-naive patients with cirrhosis treatment with SOF/LDV+RBV induced in higher costs and higher outcomes in any case (vs. TVR+PegIFN+RBV). The probability of being cost-effective at a willingness-to-pay threshold of €30,000 is 100%. In treatment-experienced non-cirrhotic patients the probability of SOF/LDV being cost-effective was 60% at a threshold of 30,000 €/QALY and 92% at 40,000 €/QALY (vs. TVR+PegIFN+RBV); in cirrhotic patients the probability of SOF/LDV+RBV being cost-effective was 100% at a threshold of 30,000 €/QALY.

Discussion {#sec018}
==========

The introduction of direct acting antivirals was the milestone in the treatment of chronic hepatitis C. Newly introduced treatment regimens have substantially increased SVR-rates, shortened treatment duration and show a favorable toxicity profile. Furthermore, these regimens allow curing patients who could not be treated previously (e.g. due to interferon intolerance, advanced cirrhosis, comorbidities).

We analyzed cost-effectiveness of SOF/LDV±RBV for the treatment of HCV genotype 1 patients. Analyses were conducted for treatment-naive and treatment-experienced patients considering presence/absence of liver cirrhosis. This regimen is recommended by the current German guideline as well as the regimen containing PTV/r/OMV/DSV±RBV and was also included our analyses \[[@pone.0169401.ref057]\].

Results show that treatment with SOF/LDV±RBV is cost-effective compared to prior standard of care considering a willingness-to-pay threshold of €30,000. The regimen of SOF/LDV even is cost saving (showed better outcomes and lower costs) in treatment-naive non-cirrhotic patients as a large part only require treatment for 8 weeks; treatment in cirrhotic patients resulted in 3,383 €/QALY. Incremental cost-effectiveness ratios were 26,426 €/QALY in non-cirrhotic and 1,397 €/QALY in cirrhotic treatment-experienced patients. Results were robust in multiple sensitivity analyses.

Several international studies have analyzed cost-effectiveness of newly introduced direct acting antivirals, especially for the US, but have not been performed for the German setting yet.

Najafzadeh et al (2015) analyzed cost-effectiveness of novel treatment regimens in treatment-naive hepatitis C patients. In genotype 1 patients, different strategies were compared to the previous standard of care (BOC+PegIFN+RBV). Treatment with SOF/LDV for 12 weeks resulted in an incremental cost-effectiveness ratio of 12,825 \$/QALY. Other interferon-free regimens showed less favorable results (12 weeks SMV/SOF: 71,445 \$/QALY; 12 weeks DCV/SOF: 63,355 \$/QALY). The authors conclude that new treatment regimens represent good long-term economic value in genotype 1 patients \[[@pone.0169401.ref009]\].

Results from another US study by Chhatwal et al. (2015) evaluated cost-effectiveness of SOF/LDV (8 or 12 weeks) compared to the old standard of care (TVR+ PegIFN+RBV and BOC+PegIFN+RBV). The analyses showed incremental cost-effectiveness ratios of 31,452 \$/QALY for non-cirrhotic and 9,703 \$/QALY for cirrhotic treatment-naive patients. In treatment-experienced patients 35,853 \$/QALY and 79,238 \$/QALY were estimated for non-cirrhotic and cirrhotic patients, respectively. Assuming a willingness-to-pay threshold of 50,000 €/QALY treatment of genotype 1 patients with SOF/LDV is cost-effective in most patient groups \[[@pone.0169401.ref008]\].

A study by Younossi et al. (2015) comes to the conclusion that SOF/ treatment LDV (8,12 or 24 weeks depending on patient characteristics) dominates other treatment strategies except for SOF+SMV (12 or 24 weeks), which provides slightly better results but is considerably more expensive. Sensitivity analyses show that costs of alternative treatment strategies have the greatest impact on study results \[[@pone.0169401.ref007]\].

Zhang et al. (2015) analyzed cost-effectiveness of recently introduced regimens, primarily considering treatment-naive patients \[[@pone.0169401.ref010]\]. In non-cirrhotic genotype 1 patients both, SOF/LDV (12 weeks) and OMV/PTV/RTV + DSV + RBV (12 weeks), dominate triple-therapy with TVR + PegIFN/RBV the prior standard of care (higher effectiveness and lower lifetime costs). In patients with cirrhosis SOF/LDV (12 weeks) dominates TVR+PegIFN+RBV, whereas treatment with OMV/PTV/RTV+DSV+RBV (12 weeks) shows an incremental cost-effectiveness ratio of 25,227 \$/QALY \[[@pone.0169401.ref010]\].

In comparing different studies, it has to be taken into account that transferability of economic evaluations is limited since healthcare systems, structures of care provision and remuneration schemes differ considerably between countries \[[@pone.0169401.ref058]\]. The comparability is made even more difficult considering differences in study design like modeling approaches, patient characteristics and treatment strategies. Therefore, there is a high need for the defining of up-to-date national data. Nevertheless, there are comparable results such as the dominant factor of treatment costs on study results. Most studies prove that treatment with SOF/LDV is cost-effective.

There are some limitations that have to be taken into account when interpreting the results of our study. Efficacy data is based on the results from different clinical trials and data for certain treatment regimens are based on a relatively small patient samples. Usually SVR-rates from clinical trials are not easily transferable into clinical practice \[[@pone.0169401.ref059]\]. Nevertheless, recent data from real-world SVR-rates show comparable SVR-rates in clinical practice. In the TRIO study SVR-rates in treatment-naive non-cirrhotic patients of 95% for an 8-week treatment with SOF/LDV and 96% for a 12-week treatment with SOF/LDV±RBV were observed \[[@pone.0169401.ref060]\]. Data on treatment-experienced patients show SVR-rates of 84% for 12 weeks of SOF/LDV, 96% for 12 weeks of SOF/LDV+RBV and 92% for 24 weeks of SOF/LDV \[[@pone.0169401.ref061]\]. German data confirm high SVR-rates for newly introduced interferon-free regimens \[[@pone.0169401.ref062]\]. A general problem is the reliability and availability of data. Extensive literature analyses were performed to determine the best available data. Furthermore, the impact of special patient types (e.g. with certain comorbidities, alcohol or drug abuse) was insufficiently taken into account as data refers to average patients. To determine cost-effectiveness in special HCV populations separate analyses and modeling approaches are necessary.

Although several studies have shown that HCV treatment with new DAA is cost-effective or even cost-saving in certain patient groups, affordability for healthcare systems and payers is doubtful. In addition to high costs of newly introduced agents, new treatment options allow to treat and cure patients who were not eligible for treatment in the past (e.g. patients with certain comorbidities or advanced liver disease, interferon-intolerant). Therefore, the number of patients available for treatment increased significantly, which stresses healthcare budgets further. Even western countries have limited or delayed access to new treatment options and restricted the use for patients with advanced liver disease \[[@pone.0169401.ref063];[@pone.0169401.ref064]\]. Prioritization of severely ill might be a short-term solution for reducing expenditure. However, it should be taken into account that a major goal of treating hepatitis C is to prevent the development of liver cirrhosis and its complications. Even if patients with liver cirrhosis are successfully treated, they are still at risk of decompensation or developing HCC \[[@pone.0169401.ref043]\].

Treatment with SOF/LDV is recommended by national and international guidelines. Our analyses showed that this treatment is cost-effective compared to the prior standard of care in genotype 1 patients (triple-therapy with TVR). Besides individual treatment costs, impact of new treatments on healthcare budgets should not be forgotten.
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PTV

:   Paritaprevir
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RBV
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PegIFN
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DCV
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:   Telaprevir
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:   Boceprevir
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:   Incremental cost-effectiveness ratio
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